Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT1190B in Relapsed/Refractory Large B-Cell Lymphoma
NCT07823829Phase 2Recruiting
- Sponsor
- CARsgen Therapeutics
- Start
- Sep 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
A Phase 2 trial of CT-1190B in diffuse large B-cell lymphoma (DLBCL), sponsored by CARsgen Therapeutics. Started Sep 2026; status: recruiting.
02
Drugs
CT-1190B
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07823829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07823829.